This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Best Stocks to Invest in for Solid Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & LivePerson (LPSN) at the moment for superb earnings acceleration.
MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 18.37% and 83.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 279% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 278.9% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers
by Zacks Equity Research
Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.
Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication
by Zacks Equity Research
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.
Wall Street Analysts Predict a 291% Upside in MacroGenics (MGNX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 291% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre Vascular (LMAT) Lags Q2 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -9.38% and 2.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 49.08% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -36.51% and -60.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 69% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 69.5% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Company News for Sep 17, 2021
by Zacks Equity Research
Companies in The News Are: F,WYNN,LVS,MGNX
MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?
by Zacks Equity Research
MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -135.71% and -13.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -69.81% and -45.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will MacroGenics (MGNX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) Stock Jumps 6.6%: Will It Continue to Soar?
by Zacks Equity Research
MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.